Company: SMNR
Filing Date: 2025-04-21
Form Type: S-4/A
Source: 0001193125-25-087342
Chunk: 604

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-21
Form: S-4/A
Chunk 604
---
 or other employees who have a significant role in New Semnur’s internal control over financial reporting and any significant changes in internal controls; |

| • |     | establishing and overseeing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting, auditing or internal control matters; |

372

| • |     | reviewing the results of management’s efforts to monitor compliance with New Semnur’s programs and policies designed to ensure compliance with laws and rules; |

| • |     | overseeing New Semnur’s programs, policies and procedures related to New Semnur’s information technology systems, information security risk management and information technology risk exposures, and the steps taken to monitor, mitigate and control such exposures and the Company’s plans to mitigate cybersecurity risks and to respond to data breaches; and |

| • |     | reviewing and discussing with management and the independent registered public accounting firm the results of the annual audit and the independent registered public accounting firm’s assessment of the quality and acceptability of New Semnur’s accounting principles and practices and all other matters required to be communicated to the audit committee by the independent registered public accounting firm under generally accepted accounting standards, the results of the independent registered public accounting firm’s review of New Semnur’s quarterly financial information prior to public disclosure and New Semnur’s disclosures in its periodic reports filed with the SEC. |

Dorman Followwill will qualify as an audit committee financial expert within the meaning of SEC regulations and each of Jay Chun, M.D., Ph.D., Dorman Followwill and Yue Alexander Wu, Ph.D. will meet the financial sophistication requirements under the Nasdaq Listing Rules. New Semnur’s independent registered public accounting firm and New Semnur management will periodically meet separately with the audit committee. The audit committee will review, discuss and assess its own performance and composition at least annually. The audit committee will also periodically review and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommend any proposed changes to the New Semnur Board for its consideration and approval. The composition and functioning of the audit committee will comply with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. New Semnur intends to comply with future requirements to the extent they become applicable to New Semnur. Compensation Committee

New Semnur’s compensation committee will consist of Dorman Followwill and Yue